

Joseph Kattan

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9372453/joseph-kattan-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

84
papers

610
citations

13
h-index

19
g-index

108
ext. papers

852
ext. citations

3.2
avg, IF

4.5
L-index

#	Paper	IF	Citations
84	Non-small cell lung cancer brain metastases and the immune system: From brain metastases development to treatment. <i>Cancer Treatment Reviews</i> , 2018 , 68, 69-79	14.4	36
83	Evaluating the impact of spirituality on the quality of life, anxiety, and depression among patients with cancer: an observational transversal study. <i>Supportive Care in Cancer</i> , 2018 , 26, 2581-2590	3.9	35
82	The Therapeutic use of human albumin in cancer patients management. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 120, 203-209	7	29
81	Oxidative stress and prostatic diseases. <i>Molecular and Clinical Oncology</i> , 2017 , 7, 723-728	1.6	25
80	Dilemma of first line regimens in metastatic pancreatic adenocarcinoma. <i>World Journal of Gastroenterology</i> , 2016 , 22, 10124-10130	5.6	19
79	Treatment of cancer patients in their last month of life: aimless chemotherapy. <i>Supportive Care in Cancer</i> , 2016 , 24, 1603-8	3.9	18
78	A comprehensive review of the current evidence for trabectedin in advanced myxoid liposarcoma. <i>Cancer Treatment Reviews</i> , 2019 , 72, 37-44	14.4	17
77	PET/CT Scanner and Bone Marrow Biopsy in Detection of Bone Marrow Involvement in Diffuse Large B-Cell Lymphoma. <i>PLoS ONE</i> , 2017 , 12, e0170299	3.7	16
76	Review and results of a survey about biosimilars prescription and challenges in the Middle East and North Africa region. <i>SpringerPlus</i> , 2016 , 5, 2113		15
75	Adding checkpoint inhibitors to tyrosine kinase inhibitors targeting EGFR/ALK in non-small cell lung cancer: a new therapeutic strategy. <i>Investigational New Drugs</i> , 2016 , 34, 794-796	4.3	14
74	A comprehensive review of the role of immune checkpoint inhibitors in brain metastasis of renal cell carcinoma origin. <i>Critical Reviews in Oncology/Hematology</i> , 2018 , 130, 60-69	7	14
73	EGFR mutation status in Middle Eastern patients with non-squamous non-small cell lung carcinoma: A single institution experience. <i>Cancer Epidemiology</i> , 2015 , 39, 1099-102	2.8	11
72	Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 153, 103029	7	11
71	A comprehensive review on the diagnosis and management of intimal sarcoma of the pulmonary artery. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 147, 102889	7	11
70	OPRM1 c.118A>G Polymorphism and Duration of Morphine Treatment Associated with Morphine Doses and Quality-of-Life in Palliative Cancer Pain Settings. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	11
69	ALK-rearranged adenocarcinoma transformed to small-cell lung cancer: a new entity with specific prognosis and treatment?. <i>Personalized Medicine</i> , 2018 , 15, 111-115	2.2	10
68	A network meta-analysis of the PD(L)-1 inhibitors in the salvage treatment of urothelial bladder cancer. <i>Immunotherapy</i> , 2018 , 10, 657-663	3.8	10

67	Targeted therapies in urothelial bladder cancer: a disappointing past preceding a bright future?. <i>Future Oncology</i> , 2019 , 15, 1505-1524	3.6	10
66	Diffuse edema suggestive of cytokine release syndrome in a metastatic lung carcinoma patient treated with pembrolizumab. <i>Immunotherapy</i> , 2017 , 9, 309-311	3.8	9
65	A new entity of abdominal squamous cell carcinoma of unknown primary. <i>European Journal of Clinical Investigation</i> , 2019 , 49, e13111	4.6	8
64	Osteonecrosis of the jaw during biyearly treatment with zoledronic acid for aromatase inhibitor associated bone loss in early breast cancer: A literature review. <i>Journal of Bone Oncology</i> , 2015 , 4, 77-9	4.5	8
63	Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer. <i>Investigational New Drugs</i> , 2016 , 34, 474-80	4.3	8
62	Could the combination of Nab-paclitaxel plus gemcitabine salvage metastatic pancreatic adenocarcinoma after folfirinox failure? A single institutional retrospective analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2017 , 41, e26-e28	2.4	7
61	Docetaxel Rechallenge in Patients with Metastatic Prostate Cancer: A Comprehensive Review. <i>Oncology Research and Treatment</i> , 2020 , 43, 299-306	2.8	7
60	The use of everolimus to reverse tamoxifen resistance in men with metastatic breast cancer: a case report. <i>Investigational New Drugs</i> , 2014 , 32, 1046-7	4.3	7
59	Perceptions of the COVID-19 vaccine among patients with cancer: a single-institution survey. <i>Future Oncology</i> , 2021 , 17, 4071-4079	3.6	7
58	Lung cancer and immunotherapy: a real-life experience from second line and beyond. <i>Future Oncology</i> , 2019 , 15, 3025-3032	3.6	6
57	Ocular and orbital side effects of ALK inhibitors: a review article. <i>Future Oncology</i> , 2019 , 15, 1939-1945	3.6	6
56	Palbociclib safety and efficacy beyond Ribociclib-induced liver toxicity in metastatic hormone-receptors positive breast cancer patient. <i>Anti-Cancer Drugs</i> , 2020 , 31, 85-89	2.4	6
55	The current state of immune checkpoint inhibitors in the first-line treatment of renal cancer. <i>Immunotherapy</i> , 2018 , 10, 1047-1052	3.8	6
54	Clinical and genetic factors associated with anxiety and depression in breast cancer patients: a cross-sectional study. <i>BMC Cancer</i> , 2021 , 21, 872	4.8	6
53	Network meta-analysis of second-line treatment in metastatic renal cell carcinoma: efficacy and safety. <i>Future Oncology</i> , 2017 , 13, 2709-2717	3.6	5
52	The role of palliative care in the last month of life in elderly cancer patients. <i>Supportive Care in Cancer</i> , 2017 , 25, 599-605	3.9	5
51	Complete Disappearance of Choroidal Metastasis from Lung Adenocarcinoma Treated with Bevacizumab and Chemotherapy. <i>Case Reports in Ophthalmological Medicine</i> , 2015 , 2015, 142408	0.7	5
50	Paraneoplastic syndromes in cancers of unknown primary: An unknown field for oncologists. <i>Bulletin Du Cancer</i> , 2019 , 106, 590-603	2.4	5

49	The management of patients with metastatic prostate cancer during the COVID-19 pandemic. <i>Future Oncology</i> , 2020 , 16, 1455-1461	3.6	4
48	TRK inhibition in soft tissue sarcomas: A comprehensive review. <i>Seminars in Oncology</i> , 2020 , 47, 73-84	5.5	4
47	Narrative review on serous primary peritoneal carcinoma of unknown primary site: four questions to be answered. <i>Annals of Translational Medicine</i> , 2020 , 8, 1709	3.2	4
46	Screening Strategies for COVID-19 in Patients With Hematologic Malignancies. <i>Frontiers in Oncology</i> , 2020 , 10, 1267	5.3	4
45	Factors associated with the time to first palliative care consultation in Lebanese cancer patients. <i>Supportive Care in Cancer</i> , 2019 , 27, 1529-1533	3.9	4
44	Clinical and Genetic Factors Associated With the Breast Cancer-Related Sleep Disorders: The "CAGE-Sleep" Study-A Cross-Sectional Study. <i>Journal of Pain and Symptom Management</i> , 2021 , 62, e46-e55	4.8	4
43	OSSMAR: An Observational Study to Describe the Use of Sunitinib in Real-Life Practice for the Treatment of Metastatic Renal Cell Carcinoma. <i>Journal of Global Oncology</i> , 2019 , 5, 1-10	2.6	3
42	Evaluation of chronic kidney disease in cancer patients: is there a preferred estimation formula?. <i>Internal Medicine Journal</i> , 2018 , 48, 1382-1388	1.6	3
41	The merit of tyrosine kinase inhibitors in the adjuvant setting of high-risk renal cell carcinoma: a meta-analysis. <i>Future Oncology</i> , 2018 , 14, 829-835	3.6	3
40	Different inhibitors for the same target in metastatic luminal breast cancer: is there any difference?. <i>Future Oncology</i> , 2018 , 14, 891-895	3.6	3
39	Characteristics of Gastric Cancer in Lebanon: a Descriptive Study from a Single Institutional Experience. <i>Journal of Gastrointestinal Cancer</i> , 2018 , 49, 21-24	1.6	3
38	Validation of the EORTC QLQ-INFO 25 questionnaire in Lebanese cancer patients: Is ignorance a Bliss?. <i>Quality of Life Research</i> , 2016 , 25, 1597-604	3.7	3
37	The optimal treatment of metastatic hormone-naive prostate cancer: abiraterone acetate or docetaxel?. <i>Future Oncology</i> , 2017 , 13, 2785-2790	3.6	3
36	The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry. <i>Cancer Epidemiology</i> , 2021 , 75, 102045	2.8	3
35	Overcoming the resistance to BRAF inhibitor by the double BRAF and MEK inhibitions in advanced melanoma: a case report. <i>Anti-Cancer Drugs</i> , 2019 , 30, 1052-1054	2.4	3
34	Bladder cancer knowledge in the Lebanese population: When ignorance could be harmful. <i>Bulletin Du Cancer</i> , 2018 , 105, 857-861	2.4	3
33	Immune checkpoint inhibitors for advanced or metastatic basal cell carcinoma: how much evidence do we need?. <i>Immunotherapy</i> , 2021 , 13, 1293-1304	3.8	3
32	An unexpected response to second line EGFR inhibitor in relapsing leptomeningeal carcinomatosis from lung adenocarcinoma raises questions on differential mechanisms of action of these agents. <i>Bulletin Du Cancer</i> , 2017 , 104, 385-387	2.4	2

31	Geriatric cancer trends in the Middle-East: Findings from Lebanese cancer projections until 2025. <i>Journal of Geriatric Oncology</i> , 2018 , 9, 120-123	3.6	2
30	Pancreatic small cell cancer. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016 , 40, 276-280	2.4	2
29	Targeting EGFR mutation in non-small-cell lung cancer: challenges and future perspectives. <i>Future Oncology</i> , 2017 , 13, 201-204	3.6	2
28	Efficacy and safety of everolimus in hormone receptor positive breast cancer in a developing country: Real-life single institutional experience. <i>Journal of Cancer Research and Therapeutics</i> , 2018 , 14, 1112-1116	1.2	2
27	Pseudo-Guillain-Barré syndrome masking acute myeloid leukemia relapse: Brief report and review. <i>Leukemia Research Reports</i> , 2015 , 4, 42-4	0.6	1
26	Epidemiologic and histologic characteristics of CNS lesions: a 20-year experience of a tertiary center in Lebanon. <i>CNS Oncology</i> , 2020 , 9, CNS55	4	1
25	Untreated chronic lymphocytic leukemia in Lebanese patients: an observational study using standard karyotyping and FISH. <i>International Journal of Hematologic Oncology</i> , 2017 , 6, 105-111	1	1
24	Solitary Laryngeal Metastasis from Transitional Cell Carcinoma of the Kidney: Clinical Case and Review of the Literature. <i>Case Reports in Otolaryngology</i> , 2015 , 2015, 595283	0.6	1
23	Fatigue in breast cancer patients on chemotherapy: a cross-sectional study exploring clinical, biological, and genetic factors.. <i>BMC Cancer</i> , 2022 , 22, 16	4.8	1
22	Safety of rituximab in a patient with chronic renal failure and low-grade non-Hodgkin lymphoma. <i>Journal of Cancer Research and Therapeutics</i> , 2015 , 11, 646	1.2	1
21	Peritoneal Tuberculosis: A Forsaken Yet Misleading Diagnosis. <i>Case Reports in Oncological Medicine</i> , 2019 , 2019, 5357049	0.9	1
20	Is there a role for the platelet-to-lymphocyte ratio in chronic lymphocytic leukemia?. <i>Future Science OA</i> , 2018 , 4, FSO344	2.7	1
19	Mesotheliomas in Lebanon: Witnessing a Change in Epidemiology. <i>Asian Pacific Journal of Cancer Prevention</i> , 2016 , 17, 4169-73	1.7	1
18	Palbociclib and letrozole in hormone-receptor positive advanced breast cancer: Predictive response and prognostic factors.. <i>Current Problems in Cancer</i> , 2022 , 46, 100859	2.3	1
17	Does tumor side represent a relevant factor for prognosis and treatment decision in metastatic colorectal cancer?. <i>Colorectal Cancer</i> , 2016 , 5, 91-93	0.8	0
16	Allied therapies against BRAF-mutated advanced colon cancer: the right plans to win the battle. <i>Colorectal Cancer</i> , 2016 , 5, 53-55	0.8	0
15	CA 15-3 predicting breast cancer relapse: beware of vitamin B12 deficiency. <i>Personalized Medicine</i> , 2018 , 15, 163-165	2.2	0
14	Chemotherapy in the management of periosteal osteosarcoma: A narrative review. <i>Journal of Bone Oncology</i> , 2021 , 30, 100389	4.5	0

13	Toxicities Associated with Docetaxel-Based Regimens in the Adjuvant Treatment of Early-Stage Breast Cancer: A Multicenter Prospective Real-Life Experience. <i>Breast Care</i> , 2018 , 13, 121-125	2.4
12	Express approval of immune checkpoint inhibitors: a conflict between science and finance. <i>Future Oncology</i> , 2016 , 12, 1215-7	3.6
11	Adjuvant tyrosine kinase inhibitors for renal cell carcinoma? No, thank you (at least for the present) reply. <i>Future Oncology</i> , 2018 , 14, 2225-2227	3.6
10	The Forgotten Complication of Recurrent Nephrolithiasis: "Squamous Cell Carcinoma of the Renal Pelvis"-A Case and Review of the Literature. <i>Case Reports in Urology</i> , 2015 , 2015, 298317	0.5
9	Impact of the new World Health Organization classification concept of neuroendocrine tumors. <i>Minerva Surgery</i> , 2018 , 73, 116-118	0.1
8	Comprehensive tumor profiling-guided therapy in rare or refractory solid cancer: A feasibility study in daily clinical practice. <i>Bulletin Du Cancer</i> , 2020 , 107, 410-416	2.4
7	Causes of death in older patients with cancer: Experience of a tertiary care center in Lebanon. <i>Journal of Geriatric Oncology</i> , 2019 , 10, 365-367	3.6
6	Learning by Debate: Innovative Tool in the Hematology-Oncology Fellowship Program. <i>Journal of Cancer Education</i> , 2021 , 1	1.8
5	COVID-19 pandemic shakes the trust between oncologists and their patients. <i>International Journal of Clinical Practice</i> , 2021 , 75, e14556	2.9
4	Total Parenteral Nutrition in Middle Eastern Cancer Patients at End of Life: Is it Justified?. <i>gulf journal of oncology, The</i> , 2019 , 1, 21-25	0.4
3	Peritoneal Carcinomatosis of Colorectal Origin in Cyclosporine Immunosuppressed Rats. <i>gulf journal of oncology, The</i> , 2020 , 1, 27-30	0.4
2	Impact and Cost-Effectiveness of Oncotype DX for Guiding Adjuvant Chemotherapy Decisions in Early Breast Cancer. <i>gulf journal of oncology, The</i> , 2021 , 1, 27-35	0.4
1	Increased psychomotor retardation and tension as short-term neuropsychiatric adverse events of immune checkpoint inhibitors: A prospective cohort study.. <i>Journal of Cancer Research and Therapeutics</i> , 2022 , 18, 140-146	1.2